BioNTech SE
BNTXNASDAQHealthcare● Active
$86.74
$-1.34(-1.52%)
Market Cap$21.9B
P/E Ratio—
52W High$124
52W Low$79.52
BioNTech SE (BNTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BNTX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$2.28
Est. -$2.52 · +9.5%
Revenue
$0.14B
Est. $0.21B · -34.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
BNTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 3, 2026 | -$2.44 | — | — | — | $0.19B | — |
| ▲ Q2 FY2026 | May 5, 2026 | -$2.52 | -$2.28 | +9.5% | $0.14B | $0.21B | -34.2% |
| ▼ Q1 FY2026 | Mar 10, 2026 | -$0.22 | -$0.38 | -72.7% | $1.07B | $0.90B | +18.1% |
| ▲ Q4 FY2025 | Nov 3, 2025 | -$1.12 | -$0.14 | +87.5% | $1.78B | $0.84B | +110.9% |
| ▲ Q3 FY2025 | Aug 4, 2025 | -$2.69 | -$1.82 | +32.3% | $0.31B | $0.18B | +72.7% |
| ▲ Q2 FY2025 | May 5, 2025 | -$2.48 | -$1.82 | +26.6% | $0.20B | $0.22B | -6.8% |
| ▲ Q1 FY2025 | Mar 10, 2025 | $0.46 | $1.15 | +148.7% | $1.23B | $1.18B | +4.4% |
| ▲ Q4 FY2024 | Nov 4, 2024 | -$1.74 | $0.89 | +151.1% | $1.39B | $0.57B | +142.9% |
Q3 FY2026
Aug 3, 2026
EPS Actual
—
EPS Est.
-$2.44
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
-$2.28
EPS Est.
-$2.52
EPS Surpr.
+9.5%
Revenue
$0.14B
Q1 FY2026
Mar 10, 2026Miss
EPS Actual
-$0.38
EPS Est.
-$0.22
EPS Surpr.
-72.7%
Revenue
$1.07B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
-$0.14
EPS Est.
-$1.12
EPS Surpr.
+87.5%
Revenue
$1.78B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
-$1.82
EPS Est.
-$2.69
EPS Surpr.
+32.3%
Revenue
$0.31B
Q2 FY2025
May 5, 2025Beat
EPS Actual
-$1.82
EPS Est.
-$2.48
EPS Surpr.
+26.6%
Revenue
$0.20B
Q1 FY2025
Mar 10, 2025Beat
EPS Actual
$1.15
EPS Est.
$0.46
EPS Surpr.
+148.7%
Revenue
$1.23B
Q4 FY2024
Nov 4, 2024Beat
EPS Actual
$0.89
EPS Est.
-$1.74
EPS Surpr.
+151.1%
Revenue
$1.39B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.64 | $0.81 | $0.97 | 1 |
| Q3 FY2027 | $-0.28 | $-0.23 | $-0.18 | 1 |
| Q2 FY2027 | $-2.38 | $-1.99 | $-1.56 | 1 |
| Q1 FY2027 | $-2.25 | $-1.88 | $-1.48 | 1 |
| Q4 FY2026 | $-1.53 | $-1.27 | $-1.00 | 1 |
| Q3 FY2026 | $0.54 | $0.89 | $1.35 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.3B | $0.4B | $0.5B | 3 |
| Q3 FY2027 | $0.8B | $1.0B | $1.1B | 3 |
| Q2 FY2027 | $0.1B | $0.2B | $0.2B | 3 |
| Q1 FY2027 | $0.1B | $0.2B | $0.2B | 3 |
| Q4 FY2026 | $0.6B | $0.7B | $0.8B | 5 |
| Q3 FY2026 | $1.1B | $1.2B | $1.2B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +9.5% | $99.35 | $95.50 | -3.88% |
| ▼ Q1 FY2026 | Mar 10, 2026 | -72.7% | $102.16 | $83.89 | -17.88% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +87.5% | $103.91 | $103.96 | +0.05% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +32.3% | $107.34 | $110.03 | +2.51% |
| ▲ Q2 FY2025 | May 5, 2025 | +26.6% | $104.94 | $101.10 | -3.66% |
| ▲ Q1 FY2025 | Mar 10, 2025 | +148.7% | $108.78 | $105.35 | -3.15% |
| ▲ Q4 FY2024 | Nov 4, 2024 | +151.1% | $111.48 | $108.97 | -2.25% |
| ▼ Q3 FY2024 | Aug 5, 2024 | -65.2% | $82.01 | $78.36 | -4.45% |
Q2 FY2026-3.88%
Report Date
May 5, 2026
EPS Beat/Miss
+9.5%
Price Before
$99.35
Price After
$95.50
Q1 FY2026-17.88%
Report Date
Mar 10, 2026
EPS Beat/Miss
-72.7%
Price Before
$102.16
Price After
$83.89
Q4 FY2025+0.05%
Report Date
Nov 3, 2025
EPS Beat/Miss
+87.5%
Price Before
$103.91
Price After
$103.96
Q3 FY2025+2.51%
Report Date
Aug 4, 2025
EPS Beat/Miss
+32.3%
Price Before
$107.34
Price After
$110.03
Q2 FY2025-3.66%
Report Date
May 5, 2025
EPS Beat/Miss
+26.6%
Price Before
$104.94
Price After
$101.10
Q1 FY2025-3.15%
Report Date
Mar 10, 2025
EPS Beat/Miss
+148.7%
Price Before
$108.78
Price After
$105.35
Q4 FY2024-2.25%
Report Date
Nov 4, 2024
EPS Beat/Miss
+151.1%
Price Before
$111.48
Price After
$108.97
Q3 FY2024-4.45%
Report Date
Aug 5, 2024
EPS Beat/Miss
-65.2%
Price Before
$82.01
Price After
$78.36
Avg Beat Reaction-1.73%
Avg Miss Reaction-11.16%
Beat Rate6 / 8 quarters
Largest Move-17.88% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BNTX ends December
BioNTech SE (BNTX) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-2.28 — beating the analyst consensus of $-2.52 by +9.5%. The next BNTX earnings date is expected around September 1, 2026.
Each quarter, investors track BNTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BNTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BNTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BNTX earnings · 5 questionsBioNTech SE's next earnings report is expected around September 1, 2026. BNTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BNTX historically reports after market close (AMC).
BNTX earnings datewhen is BNTX earningsBNTX next earnings datewhen does BNTX report earningsBNTX earnings calendar
▸ Source: FMP · BioNTech SE SEC filings · US GAAP · BioNTech SE SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026